Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Travere Therapeutics, Inc.
Bear Case (25th pct.)
-87.1% vs price
Base Case (Median)
-84.5% vs price
Bull Case (75th pct.)
-81.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| EV/EBITDA | $5.83 | -89.8% | Medium (20%) |
| EV/FCF | $11.84 | -79.2% | Medium (20%) |
Based on 2 out of 7 methods, TVTX appears overvalued at the current price of $56.93. The base case fair value of $8.83 implies 84.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.